CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Clinical trial NCT05143996 · RECRUITING

Trial details

NCT number: NCT05143996
Sponsor: Cullinan Therapeutics Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed/Refractory Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)

Start date: 2021-11-18
Primary completion: 2027-01-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.